Laser resurfacing techniqu es have become a popular means ofachie ving reju venation of dama ged skin. Int erest is great in att empting to speed re-epithelialization and healing so that pa tients can return to their normal activities as quickly as possibl e. Previous studies have demonstrated that wounds heal more quickly when they are cove red and kept mo ist than when they are left open to the air. Until now, no study has been conducte d to investigate whether the healing process of a supe rficial skin bum might be acce lerated by the use ofan autologous pla telet gel as a biologic dressing. Our study offive pigs showed that autologo us platelet gel can influ ence wound healin g by stimulating an intense infl ammatory process that leads to highly significant increases in the production ofextracellular matrices and granulation tissue. The platelet gel accelerated vascular ingrowth, increase d fi broblastic proliferation, and accelerated collagen production. However, the gel did not appear to accelerate re-epithelialization. The aggressiv e production of granulation tissu e and the accelerat ion of collagen produ ction might mean that autologous platelet gel will hav e a future role in the treatm ent ofbums because the highly vasc ularized bed it helps crea te should promote the success of skin graf ting in patients with deep partial-thickn ess and full-thickness bum s.
Introduction
Over the past several years, carbon dioxide (C0 2 ) laser ablation has been widely promot ed as a means of smoothing skin irregularities by remo ving the epidermis and superficia l derm is. The clinical result is the tightening of lax skin and the remo val of superficial blemishes. Healing of skin and soft-tissue burn injuries has been a focus of increased interest in view of the popul arity of these laser resurfac ing techn iques.
Investigations are under way to test ways of accelerating the healing proce ss, speeding re-epithelialization, and decreasing the degree and duration of ery thema, which would allow patients to resume normal daily activities in a timely fashion.' Previous studies have demonstrated that simply covering and keepin g a wound site moist improv es the rate of healin g to a greater degree than does leaving the site open to the air.' Most attempts to speed reepithelialization have focused on variations of the moist dressing.' Several new dressing material s have been marketed and are frequently used. Thes e dres sings are passive in nature in that they produce an environment condu cive to healing, but they do not actively alter the healing process.
Growth factors have also attracted intere st as potential accelerators of growth. Danilenk o et al investigated recombinant epid ermal growth factor, kera tinocy te growth factor, platelet-de rived growth factor-BB , and neu differentiation factor.' They found that the use of eac h of these grow th factors generated marginal acce lera tion of reepithelialization .
Platelet gel, a concentration of platelet-rich plasma derived from whole blood, has been anecdotally reported by Timothy Hannon, MD, (oral communication, February 1997) to expedite the healing process. Platelet s are believed to play an import ant role in primary hemostasis, wound healin g, and re-epith elialization. Platelets contain a number of cytokines that are important in angiogenesispromoting vascular ingrowth and in fibroblast proliferation , which in turn leads to increased coll agen production. These cytokines includ e platelet-derived growth factor, In clinical trials, commonly reported adverse events with RHINOCORT AQUA versus vehicle placebo were epistaxis (8% vs 5 %), pharyngitis (4% vs 3%), bronchospasm (2% vs 1%), coughing (2% vs < 1%), and nasal irritation (2% vs < 1%). The overall incidence of adverse events with RHINOCORT AQUA was similar to that observed with vehicle placebo.
Please see brief summary of full Prescribing Information on adjacent page. Salmonella/ microso me pl atetest, mousemicronucleus test, mouse lymphomatest, chromosome aberration test inhumanlymphocytes, sex-linked recessivelethaltest in Drosophilamelanogaster. and DNArepair analysis inrat hematocyteculture. Inrats,budesonidecausedadecreaseinprenatal viability andviabilityofthepupsat birthand during lactation,along witha decrease in maternal body-weight gain,at subcutaneousdoses of 20mcglkg and above(lessthan themaximum recommended daily intranasal dose inadultsonamcg/m 2 basis). No sucheff ects were noted at 5 mcg/kg (less than the maximum recommended daily intranasal dose in adults on a mcg/m 2 basis). Pregnancy: Teratogenic Effects: Pregnancy CategoryC: Budesoni dewas teratogenic and embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at subcut aneous doses of 25 mcglkg in rabbits and 500 mcg/kg in rats (approximately 2 and 16 times the maximum recommended dailyintranasal doseinadultsonamcg/m 2 basis). Inanotherstudyinrats, noteratogenic or embryocidal effects were seen at inhalation doses upto 250 mcg/kg (approximately 8 times the maximumrecommended daily intranasal dose in adultsona mcg/m 2 basis). Thereare noadequateand wellcontrolled studies inpregnant women. RHINOCORT AQUANasal Spray should beused during pregnancy onl y if the pot ential benefitjustifiesthe potential risktothe fetus. Experience with oral cort icosteroids since their introduction in pharmacologic, asopposed to physiologic, doses suggests that rodents are more prone to teratogenic eff ectsfrom cort icosteroidsthan humans. Inaddi tion, because there isanaturalincreaseincorticosteroid productionduring pregnancy, most women will requirea lower exog enous corticosteroid dose and many will notneed corticosteroid treatment during pregnancy. Nonteratogenic Effects: Hypoadrenalism may occur in inf ant s born ofmothers receivingcorticosteroids dur ingpregnancy. Such infants should becarefully observed. Nursing Mothers: It is notknown Whether budesonideis excreted in human milk. Becauseother corticosteroidsare excreted inhuman milk, caution should be exercised when RHINOCORTAQUA Nasal Spray isadmi ni steredtonursingwomen. Pediatric Use: Safetyandeffectiveness inpediatricpatientsbelow6years of age havenot been established. Controlled cli nical studies have shown that intranasal corticosteroids may cause areductioningrowthvelocity inpediatric patients. Thiseffect hasbeen observedintheabsence of laboratory evidence of hypot halamic-pituitary-adrenal (HPA)-axis suppression, suggestingthatgrowth velocity is amoresensitiveindicator ofsystemic corticosteroidexposure inpediatricpatientsthansome commonly used testsof HPA-axisfunction. Thelong-termeffectsof thisreduct ioningrowthvelocity associatedwithintranasal corticosteroids, includi ng theimpact on final adultheight, are unknown. Thepotentialfor "catch up" growth followingdiscontinuation of treatment wi th Intranasal corticosteroi ds has not been adequately studied. The growth of pediatric pat ients receiving intranasal corticosteroids,including RHINOCORT AQUA Nasal Spray, should be moni tored routinely (eg, via stadiometry). The potential growth effects of prol onged treatment shouldbewei ghedagainst cli nical benefits obtainedand theavailability ofsafeandeff ectivenoncorticosteroid treatment alternatives. To mi nimizethe syst emic effects of intranasal corticosteroids, includingRHI NOCORT AQUA Nasal Spray, each patient should be titrated to the lowest dosethateffectively controls hi s/her symptoms. Geriatric Use: Of the 2,461 patients in clinical studies of RH INOCORT AQUA Nasal Spray, 5% were 60yearsofage andover. No overall differences insafety or effectiveness were observedbetween thesesubjects and younger subjects, except for an adverse event reporting frequency of epistaxis which increased wi th age. Further, other reported clinical experience has not identified anyother differences in responses bet ween elderly and younger patients, but greater sensitivityof some older individuals cannot beruled out. ADVERSE REACTIONSTheincidence of commonadversereactionsisbasedupontwoU.S. andfivenon-U.S. controlled clinical trials in 1,526 patient s 1110 females and 239 mal es less than 18 years of age, and 635females and542males 18yearsof age and older) treatedwithRHINOCORTAQUA NasalSpray at doses upto 400 mcg once daily for 3-6weeks. Thetablebelowdescribes adverseevents occurringatan incidenceof2%or greater and more common among RHINOCORT AQUA Nasal Spray-treated patients than in placebo-treat ed patients in controlled clinical trials. The overall incidence of adverse events was similar bet ween RHINOCORT AQUA and placebo For Intranasal UseOnly.
RH
BRIEF SUMMARY INDICATIONS AND USAGE RHINOCORTAQUA Nasal Sprayisindicated forthemanagement ofnasal symptoms ofseasonal orperennial allergic rhinitisinadults andchildren sixyearsofageand older. CONTRAINDICATIONS Hypersensitivity to any oftheingredient s inthis preparationcontraindicates the use ofRHINOCORT AQUA Nasal Spray. WARNINGSThe replacement ofasystemiccorticosteroidwithatopical corticosteroidcan beaccompanied by signs of adrenal insufficiency, and in addition some patients may experience symptoms of corticosteroid wi thdrawal, eg, joint and/or muscular pain, lassitude, and depression. Patient s previously treated for prolonged periods wi thsystemiccorticosteroids andtransferr ed totopical corticosteroids should be carefUlly monitored for acute adrenal insufficiency in response to stress. In thosepatients who haveasthma or other clinical conditions requiringlong-termsystemiccorticosteroi dtreatment,toorapidadecrease insystemiccorticosteroids may cause asevereexacerbationof theirsymptoms. Patientswhoare ondrugswhichsuppress the immunesystemaremore susceptible toinf ectionsthanhealthy indivi duals. Chicken pox andmeasl es, for example, canhaveamoreserious or even fatal course innon-immunechi ldren oradultson immunosuppressant doses of corticosteroids. Insuch chil dren or adultswho havenot hadthesediseases, particular careshould betaken toavoid exposure. Howthe dose,route, and duration of corticosteroid administrati on affectsthe risk ofdeveloping adisseminated infection is not known. Thecontributionof theunderlying disease and/or prior corticosteroid treatment totherisk is also notknown. If exposed tochickenpox, prophylaxiswithvaricellazoster immunegl obulin(VZIG) may beindicat ed. An improvement in nasal symptomsmay be noted in patientswithin 10 hou rs of first usingRHI NOCORT AQUA Nasal Spray. This timetoonset issupported by anenvi ronmental exposure unit studyin seasonal allergicrhi ni tis patientswhichdemonstratedthat RHI NOCORTAQUA Nasal Spray led toastatistically significant improvement in nasal symptoms comparedto placebo by 10 hours. Furt her support comes fromaclinical study of patient s with perennialallergic rhinit iswhich demonstrate dastatisticallysi gnificant improvement innasal symptoms for both RHINOCORTAQUANasalSpray andfortheactivecomparator (mometasone furoat e) compared to pl acebo by 8 hou rs. Onset was alsoassessedinthisstudy wi thpeaknasal inspirat oryflowrat eandthi s endpoint failed toshow efficacy foreither activetreatment. Al though statistically signi ficant improvements in nasal symptoms compared to pl acebo were noted within 8-10 hou rs in these studies, about one hal f to two thirds of the ultimate clinical improvementwithRHI NOCORTAQUANasal Spray occurs over thefirst 1-2 days, andmaxi mumbenefit may not beachieved until approximately 2 weeksafter initiaf ion of treafment. Initi al assessment for responseshould be madeduring this time frameand periodi cally until the patient's symptoms are stabilized. Thepatient shouldtake themedicati onasdirectedand shouldnotexceedtheprescribeddosage.Thepatient shouldcont act thephysician if symptoms do not improve after twoweeks, or if the condi tion worsens. Patient s whoexperience recurrent episodes ofepistaxis (nosebleeds) or nasal septumdiscomfort whiletaking this medication should contact their physician. For proper use ofthisunit andtoattai nmaximumimprovement,the patientshouldreadandfollowthe accompanying patient instructions carefully. It is important to shake fhe bott le well before each use. The RHINOCORTAQUA Nasal Spray 32mcg bottlehas beenfilledwithanexcess toaccommodatethepri mi ngactivity. Thebottle should bediscarded after 120 spraysfollowi nginifial priming, since theamounf ofbudesonidedelivered per spray thereafter may be substantially less than the label ed dose. Do not transfer any remaining suspensiontoanother bottle. Drug Interactions:Themainrouteofmetabolism ofbudesonide, as well asother corticosteroids, is via cyt ochrome P450 (CYP) isoenzyme3A4 (CYP3A4). After oral administration ofketoconazole,apotent inhibitorofCYP3A4, the mean plasma con cenfration oforallyadministered budesonide increased by more than seven-fold.Concomitant administration ofother kn own inhibitors ofCYP3A4 (eg,itraconazole, clarithromycin, erythromycin, etc.) may inhibit the metabolism of, andincreasethesystemi c exposure to, budesonide (see WARNINGS andPRECAUTIONS, General).Careshould beexercised when budesonide iscoadministered wi th long-term ketoconazoleand other known CYP3A4 inhi bitors. Omeprazole, an inhibitor ofCYP2CI9, did not have effects onthepharmacokineticsoforal budesonide, whilecimetidine, primaril y aninhibitor of CYPI A2, caused a slightdecreaseinbudesonideclearance and correspondi ng increase initsoral bioavailability. Carcinogenesis, Mutagenesis, Impairment 01 Fertility: In a two-year study in Spraque-Dawley rats, budesoni decaused a statistically significant increasein the incidenceof gliomas in the male rats receiving an oral dose of 50 mcglkg (approximatelytwicethe maximumrecommendeddail yintranasal doseinadultsandchildrenonamcg/m 2 basis).
No tumorigenicity was seen in maleand femalerats atrespective oral doses up to 25 and 50mcglkg (approximately equal to and two times the maximum recommended daily int ranasal dose in adults and children on a mcg/m 2 basis, res pectively). In twoadditional two-year studies inmaleFischer andSprague-Dawley rats, budesonide caused nogliomas at an oral doseof 50 mcglkg (approximately twicethemaximum recommended daily intranasal dose in adults and children on a mcg/m 2 basis). However, in mal e Sprag ue-Dawley rats, budesonide caused a statistically significant increasein theincidenceof hepatocellul artumors at an oral doseof 50 mcglkg (approxi mately twicethemaximumrecommended dailyintra nasal dose inadu ltsandchil drenonamcg/m 2 basis). Theconcurrent referencecorticosteroi ds (prednisolone andtriamcinoloneacetoni de) inthesetwostudies showed similar find ings. Ina91-week studyinmi ce, budesonidecausednotreatment-relatedcarcinogenicityatoral doses upto200mcg/kg (approximat ely 3times themaximum recommended dailyintranasal doseinadul tsandchildren on a mcg/m 2 basis). Budesonide was not mutagenic or clastogenic in si x di fferent test systems: Ames transforming growth factor B 1, platelet-derived epidermal growth factor, platelet-derived angiogenesis factor, platelet factor 4, and platelet-activating factor. In this article, we describe our study to determine if the healing of superficial skin burns is expedited by a platelet gel held in place by a standard OpSite dressing.
Materials and methods
Processing ofthe platelet gel. Our study was conducted on five Yorkshire pigs. A baseline hematocrit and platelet count was obtained from each. Then 300 ml of whole blood was drawn from each pig via a jugular venous cutdown with a large-bore needle. The blood was drained into a sterile citrated collection bag. The pigs' average blood volume was 69.4 ml/kg of body weight, and each pig weighed approximately 25 kg, so the 300 ml of whole blood that was removed represented no more than 18% of each animal's blood volume, and the loss of blood was well tolerated by each animal. The vein was suture ligated, and the neck incision was closed.
Each blood sample was processed by a Sequestra 1000 blood-processing machine (Medtronic; Parker, Colo.) in a 125-ml Latham processing bowl. Initial processing was conducted at 5,600 revolutions per minute (rpm) to separate the plasma from the cellular elements, then at 2,400 rpm to separate the platelets from the red blood cells. Processing of each sample yielded approximately 30 ml of platelet concentrate suspended in plasma. A platelet count was obtained and recorded for each sample of platelet concentrate. Platelet counts were typically twice the baseline value in each pig. The remainder of each blood sample-approximately 270 ml of red cells and plasma-was returned to each pig via a peripheral intravenous line within 30 minutes of processing.
Creation ofthe experimental burns. The platelet concentrates were stored at room temperature while the pigs were prepared for laser burning . Following the administration of general endotracheal tube anesthesia, the hair on each pig's back was trimmed back by electric shears and then shaved off with a hand-held razor. Chlorhexidine solution was applied to the skin. Each pig's back was marked with a grid of22 equally sized squares, l l on each side of the dorsal midline (figure I). One superficial laser burn was created in each square with an UltraPulse CO 2 laser (Coherent, Inc.; Santa Clara, Calif.). The laser was set at pattern 3, density 9, 60 W, 500 mJ, and 120 pulses/ sec. Three passes were made, and mechanical debridement of any eschar was performed between passes. There was approximately a 60% overlap between adjacent laser impacts. Each burn site measured 2 x 2 ern. After creation of the burns, a punch biopsy was taken from both sides of . the dorsal midline to determine the depth of each burn.
Administration ofthe platelet gel. For each animal, the II burn sites on one side of the dorsal midline were designated as treatment sites and the l l on the other side were designated as control sites. Each treatment site received approximately 2 ml of activated platelet gel and was then covered with OpSite dressing . The control sites were covered with OpSite dressing alone. In preparing the platelet gel, 6 ml of platelet concentrate was drawn into a 10-ml syringe along with 2 ml of air. A 14-gauge Angiocath plastic catheter was attached, and 1 ml of bovine thrombin resuspended in 10% calcium chloride (1,000 U/ml of thrombin plus 100 mg/ml of calcium chloride) was drawn into the syringe with the platelet concentrate. The syringe was quickly inverted three times, and platelet concentrate was applied to each wound in 3 to 5 seconds. Antibiotics were administered to each animal at the onset of the study and continued for 5 days following the procedure. Clinical and histologic evaluations were performed on postprocedure days 2, 4, 7, and 17. The timing of the biopsies was based on data obtained in wound healing studies by Ross et al." Prior to each biopsy, each animal was anesthetized with an inhalation agent. Then two 3.5-mm punch biopsies were taken from each , one from a control site and the other from a treated site. Afterward, each biopsy site was covered with a new application of OpSite dressing. After clinical assessment and biopsy were completed, each animal was redressed with Kerlex gauze and Coban wrap, and a specially designed "pig jacket" was placed over each animal's back to protect the burn sites from further injury . The punch biopsy specimens were preserved in formalin and sectioned and examined by hematoxylin and eosin staining by a pathologist, who was blinded to the site from which each specimen was taken. Each slide was evaluated for four dependent variables: epidermal thickness, the depth of tissue necrosis, the thickness of granulation tissue, and the presence or absence of a stratum corneum.
HENDERSON, CUPP, ROSS , SH ICK, KEEFE, WE STER, HANNON , MCCONNELL The pace of re-epithelialization was slower on the treated side. In fact , both re-epithelialization and the reforming of the stratum corneum occurred twice as fast on the control side. The mean times for re-epi thelialization were 14.5 days on the treated side and 7.25 days on the control side .
Day 17 evaluation. On the final day of the experiment, the treated and control sites exhibited markedly different clinical appearances. The treated sites maintained a robust bed of granulation tissue and minimal surrounding
Statistical analysis. The four dependent variable measures were compared statistically among pigs, between treatment and control burns , and for time in days by using single-factor ana lysis of variance (ANOYA) and twoway ANOY A with repeated measur es. The two-way ANOY A also tested for any interaction effects between treatment and time. The alpha level was set at 0.05 for all ANOY A comparison s.
Results
Days 0 through 6. For the first 6 day s post-procedurally, both the treated and control sites were similar with respect to epiderm al thickness (figure 2), the depth of necrosi s (figure 3), and the thickness of granulation tissue (figure 4).
Day 7 evaluation. On day 7, the sites that had been treated with the platelet gel exhibited rob ust bed s of granulation tissu e and an intense inflammatory respon se ( figure 5 ). At the control sites, no inflammatory phase was noted clinically, and the formation of granulation tissu e was not detected histologically until an average of 11.25 days post-treatment. The difference in thickness between the treated and control site s was statistically significant (F [1, 31] =1.04; p = 0.008) .
On day 7, no stati stically sign ificant differences were seen with regard to epidermal thickness (F [I , 31] =0.13;p =0.7198), the depth of tissue necrosis (F [ I, 3 1] = 2.17; p = 0.1507 ), and the presence or absen ce of a stratum corneum (F [1, 31] = 1.31;
Surgisis is a proven biomaterial with unique features that make it ideal for use in multiple body systems and locations. Combining strength and rapid host tissue integration with biocompatibility results in a product that has advantages over synthetic biomaterials.
HENDERSON, CUPP, ROSS , SHICK, KEEFE, WESTER , HANNON, MCCONNELL erythema, while the untreated sites appeared to be well healed with minimal erythema. There was no evidence of infection in any of the anim als.
Discussion
The CO, laser is known to induce second ary tissue reactions, and its use leads to slower wound healing because of several well-known facto rs, including carbonization, thermal necrosis, inflammatory cell infiltration, lack of platelet aggreg ation, and loss of biologically active factors . There is also a decrease in the removal of necrotic tissue and ultimately a delay in neovascularization.
Re-epithelialization following laser procedures can be accelerated simply by applying a semipermeable occlusive dressing. These dressings help keep the wound moist and allow epithel ial migration to take place by limiting the formation of the thick eschar that is found in drier environments. Semipermeable occlu sive dressings (several are on the market) are cumbersome to use because they are difficult to apply and keep in place . Some occlusive dressings can even adhere to the wound and strip away newly formed epidermis, thereby creating new wounds and delaying the healing process." Althou gh these dressings appear to marginally accelerate the healing process, they are still far from ideal. Therefore, research contin ues on developing a better dressing material.
We attempted to develop an autologous platelet gel biologic dressing that would improve the re-epithelialization process following the creation of superficial laser skin burns. We believed that platelet gel would be an ideal biologic dressing because it is autologous, readily available, inexpensive, and easily prepared. Unfortunately, we found that the activated platelet gel did not speed the reepithelialization process . Instead , it induced an intense inflammatory reaction manifested as the production of robust granulation tissue . This inflammatory phase occurred much earlier in the treated burns than in the control burns .
The increased inflammatory response to the platelet gel might have resulted in higher level s of inflammatory mediators that ultim ately delayed the healing proce ss. Although this increased response is not an ideal quality for a laser resurfacing procedure (bec ause it can stimulate the formation of hypertrophic scarring), auto logous plate-602 let gel might stilI play a role in the treatment of deep partia l-thickness to full-thickness burns . A highly vascularized bed of granulation tissue might provide better vascular support for a skin graft and ultimately increase the percentage area of graft take. Further studi es of platelet gel should include its use in treating deep partialand full-thickness burn s. Such studie s might lead to improvements in the application vehicle and in the prevention of hypertrophic scars over the long term.
